Krystal Biotech Reports Positive News from Phase 2 Clinical Trial of KB103
On June 24, Krystal Biotech (KRYS) reported positive news from its Phase 2 clinical trial of KB103. The treatment was effective and well tolerated by patients suffering from recessive dystrophic epidermolysis bullosa (RDEB). In addition, the FDA awarded Regenerative Medicine Advanced Therapy (RMAT) status to Krystal Biotech for KB103. Krystal Biotech is a gene therapy […]